{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:41:16Z","timestamp":1756460476761,"version":"3.38.0"},"reference-count":20,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:p> BACKGROUND: Among hospitalized patients, a 48-hour window from time of hospitalization defines nosocomial infections and guides empiric antibiotic selection. This time frame may lead to overuse of broad-spectrum antibiotics. Our primary objective was to determine the earliest and median time since hospital admission to acquire antibiotic-resistant pathogens among patients admitted to the intensive care unit (ICU) of an academic, tertiary care hospital. METHODS: Retrospective chart review was conducted for adult patients admitted to the ICU from home or another hospital within the same health authority in 2018, to identify the time to acquisition of hospital-associated pathogens: methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, extended-spectrum beta-lactamase (ESBL)\u2013producing Enterobacterales, non-ESBL ceftriaxone-resistant Enterobacterales, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. Patients transferred from hospitals outside the health authority, admitted to ICU after 14 days of hospitalization, who were solid organ or bone marrow transplant recipients, or who were otherwise immunocompromised were excluded. RESULTS: In 2018, 1,343 patients were admitted to this ICU; 820 met the inclusion criteria. Of these, 121 (14.76%) acquired a hospital-associated pathogen in the ICU. The probability of isolating a hospital-associated pathogen by 48 hours of hospital admission was 3%. The earliest time to isolate any of these pathogens was 29 hours, and the median was 9 days (interquartile range [IQR] 3.8\u201315.6 days). CONCLUSIONS: Most patients (85.3%) in this ICU never acquired a hospital-associated pathogen. The median time to acquire a hospital-associated pathogen among the remaining patients suggests that initiating empiric broad-spectrum antibiotics on the basis of a 48-hour threshold may be premature. <\/jats:p>","DOI":"10.3138\/jammi-2021-0025","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T20:56:48Z","timestamp":1641934608000},"page":"108-116","source":"Crossref","is-referenced-by-count":1,"title":["Pattern of acquisition of hospital-associated pathogens in the ICU of an academic tertiary care hospital"],"prefix":"10.3138","volume":"7","author":[{"given":"Shazia","family":"Damji","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerrold","family":"Perrott","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salomeh","family":"Shajari","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Grant","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titus","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Vancouver General Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Harbin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Royal Inland Hospital, Kamloops, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1696","reference":[{"key":"r1","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","volume":"42","author":"Cosgrove SE.","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"r2","doi-asserted-by":"crossref","first-page":"A5","DOI":"10.1186\/1824-7288-40-S1-A5","volume":"40","author":"Mammina C","year":"2014","journal-title":"Ital J Pediatr"},{"issue":"3","key":"r3","doi-asserted-by":"crossref","first-page":"e0194210","DOI":"10.1371\/journal.pone.0194210","volume":"13","author":"Schwab F","year":"2018","journal-title":"PloS One"},{"issue":"2","key":"r4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jinf.2016.11.001","volume":"74","author":"Adrie C","year":"2017","journal-title":"J Infect"},{"key":"r5","unstructured":"5. Canadian Nosocomial Infection Surveillance Program. CNISP HAI surveillance case definitions. 2018. https:\/\/ipac-canada.org\/photos\/custom\/Members\/CNISPpublications\/2018_CNISP_HAI%20Surveillance_Case_Definitions_EN.pdf (Accessed December 6, 2021)."},{"key":"r6","unstructured":"6. National Healthcare Safety Network. Ventilator-associated event (VAE). 2020. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/10-vae_final.pdf (Accessed October 2020)"},{"issue":"16","key":"r7","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMra1403772","volume":"372","author":"Leffler DA","year":"2015","journal-title":"New Eng J Med"},{"issue":"4","key":"r8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1503\/cmaj.080239","volume":"180","author":"Mulvey MR","year":"2009","journal-title":"CMAJ"},{"issue":"1","key":"r9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","volume":"42","author":"Youssef J","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"r10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/asheducation.V2012.1.174.3798251","volume":"2012","author":"Boxer LA","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"r11","unstructured":"11. Topster.net. Hours calculator (How many hours). https:\/\/www.topster.net\/calendar\/stundenrechner.php (Accessed December 2019)."},{"issue":"5","key":"r12","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"Kalil AC","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"r13","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"Metlay JP","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"r14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"r15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM199708143370701","volume":"337","author":"Seppala H","year":"1997","journal-title":"New Eng J Med"},{"issue":"15","key":"r16","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/jama.286.15.1857","volume":"286","author":"Hyde TB","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"r17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","volume":"341","author":"Chen DK","year":"1999","journal-title":"New Eng J Med"},{"issue":"4","key":"r18","doi-asserted-by":"crossref","first-page":"e202899","DOI":"10.1001\/jamanetworkopen.2020.2899","volume":"3","author":"Rhee C","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"21","key":"r19","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"Vincent JL","year":"2009","journal-title":"JAMA"},{"key":"r20","unstructured":"20. Public Health Agency of Canada. Canadian Antimicrobial Resistance Surveillance System \u2013 report 2016. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/drugs-health-products\/antibiotic-resistance-antibiotique\/antibiotic-resistance-antibiotique-2016-eng.pdf (Accessed August 2020)."}],"container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/jammi-2021-0025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:00:25Z","timestamp":1741878025000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/jammi-2021-0025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6,1]]}},"alternative-id":["10.3138\/jammi-2021-0025"],"URL":"https:\/\/doi.org\/10.3138\/jammi-2021-0025","relation":{},"ISSN":["2371-0888","2371-0888"],"issn-type":[{"type":"print","value":"2371-0888"},{"type":"electronic","value":"2371-0888"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}